Developing effective drug formulations remains a major challenge for biopharma companies, particularly for molecules with poor solubility or complex release requirements. Quotient Sciences is exploring how machine learning and integrated manufacturin... Read more
Bringing microbiome-based therapies to patients requires more than promising clinical results. Manufacturing complex mixtures of live bacteria consistently and at commercial scale remains a major challenge. MRM Health is addressing this through its p... Read more
For people living with hereditary angioedema (HAE), sudden and unpredictable swelling attacks can disrupt daily life and require urgent treatment. Pharvaris is developing deucrictibant, an investigational oral therapy designed to provide rapid reli... Read more
For patients living with inflammatory bowel disease (IBD), persistent symptoms, repeated treatment failures and the need for lifelong therapy remain major challenges. InnoCare is developing ICP-B161, a bispecific antibody designed to block two inflam... Read more
Bavarian Nordic A/S (OMX: BAVA) launches the second tranche of the share buy-back program announced on August 21, under which the Company intends to repurchase own shares for up to DKK 750 million. The second tranche will comprise buy-back of shares ... Read more
ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, announced the successful completion of the second close of its seed financing round, securing an additional €1.6 million, bringing... Read more
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of “LEQEMBI®” (generic name: lecanemab) has been launched in Japan. LEQEMBI Pen was approved as a new rou... Read more
POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate upon standing and associated orthostatic symptoms, with no FDA-approved treatments available A single dose of baloncibart r... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
